Tacrolimus in the Treatment of Chronic and Refractory Late-Onset Immune-Mediated Adverse Effects Related to Silicone Injections

Author： Alijotas-Reig Jaume   Garcia-Gimenez Victor   Vilardell-Tarrés Miquel  

Publisher： Elsevier

ISSN： 1076-0512

Source： Dermatologic Surgery, Vol.38, Iss.1, 2012-01, pp. : 38-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Commentary: Tacrolimus in the Treatment of Chronic and Refractory Late-Onset Immune-Mediated Adverse Effects Related to Silicone Injections

By Duffy David M.  

Dermatologic Surgery, Vol. 38, Iss. 1, 2012-01 ,pp. : 48-50

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of etanercept in chronic immune-mediated disease

By Murdaca Giuseppe   Spanò Francesca   Contatore Miriam   Guastalla Andrea   Magnani Ottavia   Puppo Francesco  

Expert Opinion on Drug Safety, Vol. 13, Iss. 5, 2014-05 ,pp. : 649-661

Informa Healthcare

Access to resources Recommend Favorite

Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies: Clinical and Radiological Characteristics and Pharmacological Treatment Options

By Toussirot éric   Wendling Daniel  

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 451-469

Adis International

Access to resources Recommend Favorite

Eltrombopag: A Review of its Use in Treatment-Refractory Chronic Primary Immune Thrombocytopenia

By Garnock-Jones Karly P.  

Drugs, Vol. 71, Iss. 10, 2011-07 ,pp. : 1333-1353

Adis International

Access to resources Recommend Favorite

Cetuximab: Chronic immune-mediated demyelinating polyneuropathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1332, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite